PURPOSE: High-risk prostate cancer patients undergoing treatment often experience biochemical recurrence. The use of bisphosphonates as an adjuvant treatment delays skeletal events, yet whether or not bisphosphonates also delay metastastic development remains to be determined. MATERIALS AND METHODS: A total of 140 high-risk prostate cancer patients who were undergoing definitive treatment and who had clinically organ-confined disease and who suffered from biochemical recurrence were administered intravenous (IV) clodronate. The patients were treated with a radical retropubic prostatectomy (RP) or curative radiotherapy (RTx). Upon androgen deprivation therapy initiation, tri-monthly IV clodronate was added to the treatment to prevent bone demineralization. Twenty-six out of 60 operated cases and 45 out of 80 irradiated cases received bisphosphonate. The length of time until the first bone metastasis was recorded and analyzed. RESULTS: No statistical difference was found for the type of primary treatment (RP or RTx) on the time to the first bone metastasis (95% confidence interval [CI], 0.40 to 2.43; p=0.98). However, there was a clear advantage favoring the group that received bisphosphonate (p<0.001). The addition of bisphosphonate delayed the appearance of the first bone metastasis by seven-fold (95% CI, 3.1 to 15.4; p<0.001). CONCLUSION: Treatment with tri-monthly IV clodronate delayed the time to the first bone metastasis in high-risk prostate cancer patients who were experiencing an increase in the prostate specific antigen level after definitive treatment.
PURPOSE: High-risk prostate cancerpatients undergoing treatment often experience biochemical recurrence. The use of bisphosphonates as an adjuvant treatment delays skeletal events, yet whether or not bisphosphonates also delay metastastic development remains to be determined. MATERIALS AND METHODS: A total of 140 high-risk prostate cancerpatients who were undergoing definitive treatment and who had clinically organ-confined disease and who suffered from biochemical recurrence were administered intravenous (IV) clodronate. The patients were treated with a radical retropubic prostatectomy (RP) or curative radiotherapy (RTx). Upon androgen deprivation therapy initiation, tri-monthly IV clodronate was added to the treatment to prevent bone demineralization. Twenty-six out of 60 operated cases and 45 out of 80 irradiated cases received bisphosphonate. The length of time until the first bone metastasis was recorded and analyzed. RESULTS: No statistical difference was found for the type of primary treatment (RP or RTx) on the time to the first bone metastasis (95% confidence interval [CI], 0.40 to 2.43; p=0.98). However, there was a clear advantage favoring the group that received bisphosphonate (p<0.001). The addition of bisphosphonate delayed the appearance of the first bone metastasis by seven-fold (95% CI, 3.1 to 15.4; p<0.001). CONCLUSION: Treatment with tri-monthly IV clodronate delayed the time to the first bone metastasis in high-risk prostate cancerpatients who were experiencing an increase in the prostate specific antigen level after definitive treatment.
Authors: W U Shipley; H D Thames; H M Sandler; G E Hanks; A L Zietman; C A Perez; D A Kuban; S L Hancock; C D Smith Journal: JAMA Date: 1999-05-05 Impact factor: 56.272
Authors: Matthew R Smith; James Eastham; Donald M Gleason; Daniel Shasha; Simon Tchekmedyian; Norman Zinner Journal: J Urol Date: 2003-06 Impact factor: 7.450
Authors: Darren E Whittemore; Eric J Hick; Mark R Carter; Judd W Moul; Alejandro J Miranda-Sousa; Wade J Sexton Journal: J Urol Date: 2008-02 Impact factor: 7.450
Authors: I J Diel; E F Solomayer; S D Costa; C Gollan; R Goerner; D Wallwiener; M Kaufmann; G Bastert Journal: N Engl J Med Date: 1998-08-06 Impact factor: 91.245
Authors: Fred Saad; Donald M Gleason; Robin Murray; Simon Tchekmedyian; Peter Venner; Louis Lacombe; Joseph L Chin; Jeferson J Vinholes; J Allen Goas; Bee Chen Journal: J Natl Cancer Inst Date: 2002-10-02 Impact factor: 13.506
Authors: M Dror Michaelson; Donald S Kaufman; Hang Lee; Francis J McGovern; Philip W Kantoff; Mary Anne Fallon; Joel S Finkelstein; Matthew R Smith Journal: J Clin Oncol Date: 2007-03-20 Impact factor: 44.544
Authors: Trevor Powles; Alexander Paterson; Eugene McCloskey; Phil Schein; Bobbi Scheffler; Alwynne Tidy; Sue Ashley; Ian Smith; Lars Ottestad; John Kanis Journal: Breast Cancer Res Date: 2006-03-15 Impact factor: 6.466